These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 1655284)

  • 21. A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms' tumor) in a patient with Denys-Drash syndrome.
    Sakai A; Tadokoro K; Yanagisawa H; Nagafuchi S; Hoshikawa N; Suzuki T; Kohsaka T; Hasegawa T; Nakahori Y; Yamada M
    Hum Mol Genet; 1993 Nov; 2(11):1969-70. PubMed ID: 8281164
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
    Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
    Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Software and database for the analysis of mutations in the human WT1 gene.
    Jeanpierre C; Béroud C; Niaudet P; Junien C
    Nucleic Acids Res; 1998 Jan; 26(1):271-4. PubMed ID: 9399851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome.
    Vicanek C; Ferretti E; Goodyer C; Torban E; Moffett P; Pelletier J; Goodyer P
    Kidney Int; 1997 Sep; 52(3):614-9. PubMed ID: 9291179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
    Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
    Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dominant negative mutations in the Wilms tumour (WT1) gene cause Denys-Drash syndrome--proof that a tumour-suppressor gene plays a crucial role in normal genitourinary development.
    Hastie ND
    Hum Mol Genet; 1992 Aug; 1(5):293-5. PubMed ID: 1338905
    [No Abstract]   [Full Text] [Related]  

  • 27. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
    Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
    Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic analysis of two female patients with incomplete Denys-Drash syndrome.
    Ohta S; Ozawa T; Shiraga H; Fuse H
    Endocr J; 2000 Dec; 47(6):683-7. PubMed ID: 11228042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exon skipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms' tumor and severe genital malformations.
    Schneider S; Wildhardt G; Ludwig R; Royer-Pokora B
    Hum Genet; 1993 Jul; 91(6):599-604. PubMed ID: 8393425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
    Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
    Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The third zinc finger of the WT1 gene is mutated in Wilms' tumour but not in a broad range of other urogenital tumours.
    Quek HH; Chow VT; Tock EP
    Anticancer Res; 1993; 13(5A):1575-80. PubMed ID: 8239537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Glomerulopathy in Denys-Drash syndrome. Case report of a model disease].
    Stallmach T; Neuhaus TJ; Kösters R; Hailemariam S
    Pathologe; 1998 May; 19(3):230-4. PubMed ID: 9648150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome.
    Baird PN; Santos A; Groves N; Jadresic L; Cowell JK
    Hum Mol Genet; 1992 Aug; 1(5):301-5. PubMed ID: 1338906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The human sex-determining gene SRY is a direct target of WT1.
    Hossain A; Saunders GF
    J Biol Chem; 2001 May; 276(20):16817-23. PubMed ID: 11278460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
    Bardeesy N; Zabel B; Schmitt K; Pelletier J
    Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
    [No Abstract]   [Full Text] [Related]  

  • 36. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms.
    Klamt B; Koziell A; Poulat F; Wieacker P; Scambler P; Berta P; Gessler M
    Hum Mol Genet; 1998 Apr; 7(4):709-14. PubMed ID: 9499425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.
    Schumacher V; Schärer K; Wühl E; Altrogge H; Bonzel KE; Guschmann M; Neuhaus TJ; Pollastro RM; Kuwertz-Bröking E; Bulla M; Tondera AM; Mundel P; Helmchen U; Waldherr R; Weirich A; Royer-Pokora B
    Kidney Int; 1998 Jun; 53(6):1594-600. PubMed ID: 9607189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel WT1 gene mutation in a newborn infant diagnosed with Denys-Drash syndrome.
    Hakan N; Aydin M; Erdogan O; Cavusoglu YH; Aycan Z; Ozaltin F; Zenciroglu A; Apaydin S; Gunes R; Sahin G; Cinar G; Okumus N
    Genet Couns; 2012; 23(2):255-61. PubMed ID: 22876585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA binding by the Wilms tumor suppressor zinc finger proteins.
    Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.